MX2018005589A - Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas. - Google Patents

Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.

Info

Publication number
MX2018005589A
MX2018005589A MX2018005589A MX2018005589A MX2018005589A MX 2018005589 A MX2018005589 A MX 2018005589A MX 2018005589 A MX2018005589 A MX 2018005589A MX 2018005589 A MX2018005589 A MX 2018005589A MX 2018005589 A MX2018005589 A MX 2018005589A
Authority
MX
Mexico
Prior art keywords
uveitis
methods
macular edema
compositions
treatment
Prior art date
Application number
MX2018005589A
Other languages
English (en)
Spanish (es)
Inventor
Aavali Sridhara Sundaram Preethi
Buggage Ronald
W C Karen
Corp Dit Genti Valérie
A Erickson Kristine
Mery-Mignard Dominique
Varona Rafael
L Vitti Robert
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2018005589A publication Critical patent/MX2018005589A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2018005589A 2015-11-03 2016-11-03 Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas. MX2018005589A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562250269P 2015-11-03 2015-11-03
EP16306166 2016-09-14
US201662408391P 2016-10-14 2016-10-14
PCT/US2016/060344 WO2017079443A1 (en) 2015-11-03 2016-11-03 Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same

Publications (1)

Publication Number Publication Date
MX2018005589A true MX2018005589A (es) 2018-11-09

Family

ID=57018106

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005589A MX2018005589A (es) 2015-11-03 2016-11-03 Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
MX2022011972A MX2022011972A (es) 2015-11-03 2018-05-03 Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022011972A MX2022011972A (es) 2015-11-03 2018-05-03 Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.

Country Status (13)

Country Link
US (2) US10968278B2 (cg-RX-API-DMAC7.html)
EP (1) EP3371224A1 (cg-RX-API-DMAC7.html)
JP (4) JP7272794B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180073680A (cg-RX-API-DMAC7.html)
CN (1) CN108473583A (cg-RX-API-DMAC7.html)
AU (2) AU2016348418B8 (cg-RX-API-DMAC7.html)
BR (1) BR112018008900A8 (cg-RX-API-DMAC7.html)
CA (1) CA3003874A1 (cg-RX-API-DMAC7.html)
IL (1) IL319993A (cg-RX-API-DMAC7.html)
MX (2) MX2018005589A (cg-RX-API-DMAC7.html)
SG (1) SG11201803654TA (cg-RX-API-DMAC7.html)
TW (3) TWI729022B (cg-RX-API-DMAC7.html)
WO (1) WO2017079443A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CA3003874A1 (en) 2015-11-03 2017-05-11 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
JP7504871B2 (ja) 2018-08-29 2024-06-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 関節リウマチを有する対象を治療するための方法および組成物
KR20210122810A (ko) 2019-01-31 2021-10-12 사노피 바이오테크놀로지 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
EP3959240A1 (en) 2019-04-24 2022-03-02 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
AU2020288561A1 (en) 2019-06-04 2021-12-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating pain in subjects with rheumatoid arthritis
JP2022537555A (ja) 2019-06-20 2022-08-26 武田薬品工業株式会社 ウイルスベースの遺伝子療法による治療方法
AR123948A1 (es) * 2020-10-28 2023-01-25 Regenxbio Inc ANTICUERPOS ANTI-TNF-a VECTORIZADOS PARA INDICACIONES OCULARES
CA3264497A1 (en) * 2022-10-24 2024-05-02 F. Hoffmann-La Roche Ag Predicting response to il-6 antagonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU218140B (hu) 1991-04-25 2000-06-28 Chugai Seiyaku Kabushiki Kaisha Humán interleukin-6-receptorral szembeni átalakított humán antitest
ES2384222T3 (es) 1994-10-07 2012-07-02 Chugai Seiyaku Kabushiki Kaisha Inhibición del crecimiento anómalo de células sinoviales utilizando un antagonista de IL-6 como principio activo
UA66757C2 (en) 1996-02-26 2004-06-15 Advanced Res & Tech Inst Ophthalmologic composition of carbonic anhydrase inhibitors, method for treating or preventing macular edema or age-related macular degeneration
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
EP1751612B1 (en) 2004-05-06 2009-02-25 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Methods and compositions for the treatment of uveitis
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
CN102089326B (zh) * 2008-05-13 2014-12-31 诺维莫尼公司 抗白细胞介素-6/白细胞介素-6受体的抗体及其使用方法
CN102883748A (zh) 2010-05-07 2013-01-16 爱克索马技术有限公司 治疗IL-1β相关状况的方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
BR112015010360A8 (pt) * 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
JP6657089B2 (ja) 2013-11-22 2020-03-04 サノフィ・バイオテクノロジー 関節リウマチを治療するための組成物およびこれを使用する方法
IL295414B1 (en) 2014-03-27 2025-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
CA3003874A1 (en) * 2015-11-03 2017-05-11 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same

Also Published As

Publication number Publication date
JP2023062062A (ja) 2023-05-02
JP2018532804A (ja) 2018-11-08
IL319993A (en) 2025-06-01
SG11201803654TA (en) 2018-05-30
AU2016348418B8 (en) 2023-10-19
TWI729022B (zh) 2021-06-01
KR20180073680A (ko) 2018-07-02
TW202339795A (zh) 2023-10-16
WO2017079443A8 (en) 2017-07-06
MX2022011972A (es) 2022-10-20
JP2025020227A (ja) 2025-02-12
AU2023233110A1 (en) 2023-10-05
BR112018008900A2 (pt) 2018-11-06
AU2016348418B2 (en) 2023-10-12
US10968278B2 (en) 2021-04-06
CN108473583A (zh) 2018-08-31
AU2016348418A8 (en) 2023-10-19
TW201729828A (zh) 2017-09-01
JP2021193120A (ja) 2021-12-23
US20210301027A1 (en) 2021-09-30
JP7581399B2 (ja) 2024-11-12
CA3003874A1 (en) 2017-05-11
JP7272794B2 (ja) 2023-05-12
BR112018008900A8 (pt) 2019-02-26
TW202138001A (zh) 2021-10-16
US20170166646A1 (en) 2017-06-15
TWI786636B (zh) 2022-12-11
AU2016348418A1 (en) 2018-06-21
EP3371224A1 (en) 2018-09-12
WO2017079443A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
MX2018005589A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CO2019012353A2 (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1
JOP20170170B1 (ar) صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
CL2018002878A1 (es) Composiciones y anticuerpos anti-tim-3.
MX2024006564A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
ECSP17063327A (es) Receptores de antígeno quiméricos anti–dll3 y métodos de uso
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EA201792616A1 (ru) Средства, пути применения и способы лечения синуклеопатии
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
EA201691541A1 (ru) Новые анти-baff антитела
MX2021007768A (es) Anticuerpos anti-ctla4 y metodos de uso de los mismos.
GT201700188A (es) Anticuerpos contra tau y sus usos
CR20180105A (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX377190B (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
MX2018013072A (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
MX378108B (es) Anticuerpos anti-met y composiciones.
MX2018005070A (es) Composición para el tratamiento de cáncer con expresión del igf-1r.
MX2019007738A (es) Anticuerpos contra el vih ampliamente neutralizantes y métodos de uso de ellos.
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.